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Ulas D. Bayraktar, Richard E. Champlin, Stefan O. CiureaHaploidentical stem cell transplantation is an attractive form of transplantation because of the immediate
donor availability, ease of stem cell procurement, and the possibility to further collect donor cells for cellular
therapy. Historically, maintaining T cells in the graft has been associated with very high rates of graft-versus-
host-disease (GVHD), whereas T cell–depleted haploidentical transplantation has been limited by a higher
incidence of graft rejection and nonrelapse mortality related to infectious complications as a result of delayed
immune reconstitution posttransplantation. Recent approaches have attempted to eliminate the alloreactive
T cells to prevent GVHD posttransplantation. Administration of high-dose cyclophosphamide early post-
transplantation in combination with tacrolimus and mycophenolate mofetil has produced engraftment and
GVHD rates similar to HLA-matched sibling transplants, suggesting that the most important barriers against
successful haploidentical transplantation can be overcome. Future directions should focus on optimizing con-
ditioning regimens for different diseases and prevention of disease relapse posttransplantation.
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posttransplantation cyclophosphamideINTRODUCTION
Hematopoietic stem cell transplantation is the
treatment of choice for patients with high-risk or ad-
vanced hematologic malignancies [1]. Approximately
70% of patients do not have a matched related donor
available for transplantation [2]. For these patients,
a matched unrelated donor (MUD) transplant pro-
duces similar transplant outcomes [3,4]. However,
a matched donor can be identified for only 50% to
60% of patients and the donor search and acquisition
process requires a median of 4 months. Patients are
most likely to have an HLA match among individuals
from their own racial and ethnic group. Therefore,
the chance of finding such donors varies widely
among different major ethnicities [5]. A recent review
of all 2117 MUD transplant recipients performed at
the University of Texas M.D. Anderson Cancer Cen-
ter in the past 25 years revealed that 1677 patients
(79.2%) were Caucasian, 271 patients (12.8%) wereDepartment of Stem Cell Transplantation and Cellular
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6/j.bbmt.2011.08.001Hispanics, 109 (5%) were African-Americans, and
33 (1.5%) were Asians. A similar racial distribution
was noted for patients who received a 9 of 10 MUD
at our institution during the same period of time
(N 5 122) (79.1% Caucasians, 12.2% Hispanics,
6.5% African-Americans, 2.4% Asians). Identification
of a MUD is even more challenging for mixed-race in-
dividuals. Interracial/interethnic marriages are at an
all-time high [6], and recent data from the 2010 U.S.
Census Bureau indicates that approximately 3% of
the U.S. population identifies itself as mixed race,
and the percentage of mixed-race individuals has in-
creased by approximately 50% compared with the
year 2000 [7].
Haploidentical stem cell transplantation (Hap-
loSCT) is an alternative treatment usually option for
such patients. Parents, children, and half siblings are
potential haploidentical donors, so these donors are
readily available for most patients. The use of
haploidentical-related donors for transplantation has
the advantage of almost universal and immediate avail-
ability of donor stem cells for transplantation and
maintains the possibility to further collect donor cells
for cellular therapy, if needed. Here, we review the past
experience and future directions in haploidentical
transplantation.
Haploidentical transplantations initially performed
in the late 1970s were associated with severe graft-
versus-host disease (GVHD) and poor outcomes [8,9].
Of 105 patients who underwent HaploSCT without
T cell depletion at the Fred Hutchinson Cancer
Center, almost 20% had graft failure and 70%
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a syndromeofmultiorgan failure (manifested as seizure,
pulmonary edema, intravascular hemolysis, and renal
failure) leading todeath after infusionof unmanipulated
haploidentical stem cells, likely related to alloreactiveT
cells.T CELL–DEPLETED HAPLOIDENTICAL
TRANSPLANTATION
Depletion of T cells effectively prevents GVHD in
animal models [12-14]. Human trials using T cell–
depleted (TCD) bone marrow transplantation has
been extensively evaluated [15-17]. Ex vivo TCD
HaploSCT was first performed successfully in an
acute leukemic infant [18]. This method proved useful
in preventing GVHD and was effectively used in
patients with severe combined immune deficiency
who could not build a significant host immune re-
sponse against the transplanted donor cells. Unfortu-
nately, extensive T cell depletion of the bone marrow
(BM) graft results in an increased risk of graft rejection,
occurring in up to 50% of cases [19]. The risk of graft
rejection could be reduced by intensifying the condi-
tioning regimen [20,21], in vivo T cell depletion with
antibodies [22], and increasing the BM inoculum
(number of CD341 cells infused) [12].
Aversa et al. [23] reported on the successful use of
"mega-dose" CD341 cells TCD HaploSCT using
granulocyte-colony stimulating factor (G-CSF) mobi-
lized peripheral blood stem cells (PBSCs) and positive
selection of CD341 cells as a T cell–depletionmethod,
obtaining.10 106 CD341 cells/kg in the final prod-
uct. The number of T cells in the graft was reduced sig-
nificantly by 3 to 3.5 logs, and the conditioning
regimen was intensified with the addition of thiotepa
to total body radiation and cyclophosphamide.ThePe-
rugia group achieved primary engraftment in 96 of 104
patients with a revised protocol using positively se-
lected CD341 PBSCs [24]. Although GVHD rates
were low and relapse incidence was only 16% among
those transplanted in remission, the nonrelapsemortal-
ity (NRM) rate approached 40% primarily because of
opportunistic infections, likely related to the delayed
immunologic reconstitution. Furthermore, a survey
by the European Blood andMarrowTransplantGroup
reported an NRM approaching 50% at 2 years among
266 patients with high-risk acute leukemia who under-
went fully HaploSCT with TCD PBSCs [25]. More
than one-half of these deaths were because of infec-
tions, again highlighting the need for new approaches
to decrease treatment-related mortality and improve
the immunologic reconstitution after HaploSCT.
Positive selection of CD341 cells depletes T cells
as well as natural killer cells (NK cells), which could
be exploited to improve efficacy and safety ofHaploSCT. "Alloreactive"NKcellsmay help eradicate
the remaining leukemia cells after the conditioning
regimen and clear residual recipient lymphocytes and
antigen-presenting cells (APCs), potentially prevent-
ing graft rejection and GVHD [26]. Furthermore,
NK cells are an important part of the antiviral immu-
nity [27], potentially adding to the fight against viral
infections, which are the most common cause of infec-
tious complications post-HaploSCT [28]. Conse-
quently, new regimens involving negative depletion
of T cells by immunomagnetic beads were developed
[29,30]. Bethge et al. [31] later adapted this approach
to adults using negative depletion of CD3- and
CD19-positive cells and reduced-intensity condition-
ing (RIC). Twenty-nine patients with hematologic
malignancies underwent HaploSCT with CD3/
CD19-depleted peripheral blood grafts after an RIC
including fludarabine, melphalan, and thiotepa.
Median CD34 cell content of the grafts was consider-
ably less than that given by the Perugia group after
CD34-positive selection (7.6  106/kg versus 13.8 
106/kg). All but 1 patient engrafted with full donor chi-
merism. Although the regimen was well tolerated,
NRM in the first 100 days approached 20%. Incidence
of grade II-IV GVHD was 48%. Twenty patients died:
12 because of relapse, 7 because of infections, and 1 be-
cause of GVHD. One-year overall survival (OS) re-
mained at 35%. Although this approach demonstrated
that megadoses of stem cells higher than 10  106/kg
and full myeloablative conditioning were not required
for successful engraftment inHaploSCT, it was compli-
cated with higher relapse rates, possibly because of
reduced intensity of the conditioning and persistently
delayed immune reconstitution.IMPROVEMENTS IN EX VIVO T CELL–
DEPLETED HAPLOIDENTICAL
TRANSPLANTATION
Infusion of Regulatory T Cells (Tregs)
Tregs suppress immune reactivity that maintains
tolerance to self-antigens, and depletion of Tregs re-
sults in a spectrum of autoimmune diseases [32-35].
In murine models of HLA-mismatched transplanta-
tion, Tregs suppressed lethal GVHD [36] and favored
posttransplantation immune reconstitution when co-
infused with conventional T cells [37]. The Perugia
group recently reported on a protocol using infusion
of donor Tregs following a T cell–depleted haploi-
dentical transplant as a means to further reduce the
risk of GVHD [38]. Donor Tregs were selected and in-
fused after a myeloablative conditioning regimen fol-
lowed, 4 days later, by infusion of TCD mega-dose
PBSCs and donor conventional T cells. No posttrans-
plantation immunosuppression was administered. Of
28 patients treated, 26 achieved primary sustained
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GVHD (aGVHD). No patient developed chronic
GVHD (cGVHD). A wide T cell repertoire developed
rapidly. Thirteen patients died, 8 because of opportu-
nistic infections. At a median follow-up of 12 months,
12 patients were alive and disease-free. This study
demonstrated the feasibility of adoptive immunother-
apy with Tregs and their potential application to mod-
ify GVHD and enhance immune reconstitution after
hematopoietic stem cell transplantation. However,
the high treatment-related mortality of 50% in this
group of patients remains a concern [38].
Infusion of Selectively Allodepleted T Cells
Although the use ofTregs with conventional T cells
in this TCD transplant model may improve early im-
mune reconstitution, Tregs may also have an inhibitory
effect on desirable bystander T cell responses [39,40].
Alternatively, infusion of T cells depleted of cells
alloreactive to recipient antigens may improve
immune reconstitution while preserving graft-versus-
tumor effect, without causing GVHD. Currently
available alloreactive T cell depletion methods rely on
cocultures with recipients’ cells to activate the alloreac-
tive cells, followed by either targeting the surface activa-
tion markers or using photoactive dyes that are
preferentially retained in activated T cells [41].
Amrolia et al. [42] investigated the use of an anti-
CD25 immunotoxin to deplete alloreactive lympho-
cytes in TCDHaploSCT patients. This group infused
104-105 cells/kg allodepleted lymphocytes on 30, 60,
and 90 days posttransplantation in 16 patients (median
age 9 years) [42]. One patient developed graft failure
and subsequently had an autologous reconstitution.
Two patients developed grade II and IV aGVHD.
Patients who received higher doses of lymphocytes
exhibited more rapid recovery of T cells. A higher
polyclonal distribution of Vb receptor gene was noted
at 4 months after transplantation compared with retro-
spective controls who did not receive T cell add-back.
However, at a median follow-up of 33 months, 9 pa-
tients died (56%) because of relapse disease (5), infec-
tion (3), and interstitial pneumonitis (1). Despite its
small size, this study confirmed the safety of the addi-
tion of selectively allodepleted donor T cells after
HaploSCT. However, it should be noted that the
allodepletion method based on CD25 expression also
depletes Tregs. Further studies are needed to assess
the efficacy of this approach.
Anti-HLA Antibodies and Graft Rejection in
TCD HaploSCT
To address the high toxicity of the myeloablative,
total body irradiation–based conditioning regimens
used in the aforementioned trials, we studied the feasi-
bility of a myeloablative yet RIC regimen consisting offludarabine, melphalan, and thiotepa for patients with
advanced hematologic malignancies undergoing TCD
HaploSCT [43]. Of 28 patients enrolled in this phase
II trial, 22 (79%) achieved primary engraftment,
whereas 5 achieved secondary engraftment either after
a second transplant (n 5 4) or infusion of cryopre-
served autologous cells (n 5 1). None of the patients
developed grade III-IV aGVHD, and 4 of 21 patients
developed cGVHD as seen in the European trials after
TCD HaploSCT. NRM was 40% at 1 year, and most
of the deaths were related to infections, which made us
change our approach to using a T cell–replete (TCR)
allograft to improve immune reconstitution posttrans-
plantation and hopefully decrease the NRM associated
with infectious complications [44]. In addition, this
study revealed a higher rate of graft failure in the
TCD HaploSCT patients, even if megadoses of
CD341 cells were used (median number of CD341
cells: 10.2  106/kg). This prompted us to look for
other causes of graft rejection in these patients and
studied the relationship between the donor-specific
anti-HLA antibodies (DSA) identified with a solid-
phase fluorescent assay and graft failure, based on the
association found between anti-HLA antibodies and
graft rejection in solid organ transplantation [45,46].
Twenty-four patients were tested for the presence of
DSA in pretransplantation serum specimens. Three
of 4 patients (75%) with DSA at the time of transplan-
tation developed primary graft failure compared with
only 1 of 20 patients (5%) who did not have DSA, sug-
gesting that the presence of DSA is an important cause
of graft rejection in patients undergoing TCD
HaploSCT [47]. Future studies should attempt to
decrease antibody levels before infusion of CD341
cells to prevent graft failure, if another donor is not
available for such patients.T CELL REPLETE HAPLOIDENTICAL
TRANSPLANTATION
Because of delayed immunologic reconstitution
and higher treatment-related mortality after TCD
HaploSCT, alternative transplant options have been
sought.Maintaining the T cells in the graft while effec-
tively preventing the development of GVHD post-
transplantation could represent a viable alternative to
TCD HaploSCT.
High-Dose Posttransplantation
Cyclophosphamide for GVHD Prevention
Historic experience clearly showed that infusion of
a TCR haploidentical graft without effective GVHD
prevention was associated with unacceptable toxicity
[10]. One of the most promising ways of eliminating
alloreactive T cells responsible for both graft rejection
andGVHD is the use of cyclophosphamide (Cy) in the
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and host T cells recognize each other as foreign and
generate bidirectional alloreactivity. The use of post-
transplantation Cy was initially used in the 1960s by
Barenbaum and Brown [48], who showed that it can
prevent skin graft rejection when administered 2 to 3
days after allografting in a mouse model. Similarly,
its use in the early posttransplantation period has
been shown to eliminate alloreactive T cells and
facilitate engraftment of donor cells as the hemato-
poietic stem cells are quiescent cells, which are resis-
tant to cytotoxic chemotherapy because of their high
levels of aldehyde dehydrogenase [49].
Luznik and colleagues [50] subsequently showed
that posttransplantation Cy can attenuate lethal and
nonlethal GVHD in mice and prolong their survival.
O’Donnell et al. [51] demonstrated the feasibility of us-
ing posttransplantation Cy in a small cohort of patients
with high-risk hematologic malignancies treated with
a nonmyeloablative conditioning regimen, TCR haplo-
identical BM stem cells, and posttransplantation Cy of
50 mg/kg on day 3 after transplantation. Relatively low
rates of graft failure and GVHD were noted among 13
patients treated [51]. In a more recent update, Luznik
et al. [52] used Cy on posttransplantation days 3 and 4
and intensified mycophenolate mofetil (MMF) dosing
from twice to three times daily, to further decrease the
graft failure and GVHD rates. Although graft rejection
occurred in 9 of 66 evaluable patients, 8 of those experi-
enced recovery of autologous hematopoiesis. Grade
III-IV aGVHD incidence was 6%. Chronic GVHD in-
cidence was lower among those who received 2 doses of
posttransplantation Cy (5%) compared with those who
received 1 dose (25%). Although NRM rate was rela-
tively low at 15% at 1 year posttransplantation, relapse
incidence at 2 years was 58% [52].
Despite the success of using posttransplantation
Cy in reducing GVHD and graft failure rates without
increased NRM rates, relapses arose as a major treat-
ment failure that could be attributed primarily to the
use of nonmyeloablative conditioning, especially for
patients with myeloid malignancies and acute leuke-
mias. Recently, the Johns Hopkins group presented
its findings in 17 patients after HaploSCT using mye-
loablative conditioning with busulfan, Cy, and total
body irradiation, and posttransplantation Cy [53].
The cumulative incidence of NRM at 100 days was
higher at 18%, whereas GVHD rates were acceptable
and none of the evaluable patients had graft rejection
[53]. However, the data are not mature, and further
studies are needed to establish the safety and efficacy
of posttransplantation Cy after myeloablative condi-
tioning.
More recently, the Blood and Marrow Transplant
Clinical Trials Network conducted 2 parallel multi-
center phase II trials of double umbilical cord blood
transplantation and TCR HaploSCT for individualswith lymphoma or leukemia [54]. The conditioning
regimen and GVHD prophylaxis in the HaploSCT
trial were identical to those previously reported by
Luznik et al. [52]. One-year NRM and progression-
free survival were 7% and 48%, reproducing Johns
Hopkins’ results in a multicenter trial. Yet again, re-
lapse was the primary cause of death, attributed pri-
marily to the use of nonmyeloablative conditioning
for patients with leukemia, which represented more
than one-half of the patients treated in this trial.
We are investigating the use of posttransplantation
Cy in a phase II clinical trial ongoing at the M.D.
Anderson Cancer Center. To date, more than 40 pa-
tients were treated, and outcomes for the first 24 con-
secutive patients were recently reported in abstract
format [44]. Patients received the same conditioning
regimen (fludarabine, melphalan, thiotepa) previously
reported by us in TCD HaploSCT, followed by post-
transplantationCy on days13 and14, tacrolimus, and
MMF. Median age was 47 years (range: 24-65 years)
and 66% were ethnic minority patients. All 23 evalu-
able patients engrafted with 100% donor cells after a
median of 19 days. Day 100 NRM was 14% for first
transplants, and no patient \50 years of age died
because of treatment-related mortality. Grade II-IV
aGVHD occurred in only 4 patients, all immediately
after the MMF was abruptly discontinued on day 35
posttransplantation. We are now continuing MMF
until day 100 posttransplantation and tapering weekly
thereafter. After a median follow-up of 6 months for
these patients (range: 3-22 months), OS was 71% for
first transplants and progression-free survival was 80%
for patients in remission at the time of transplantation.
No patient died of NRM after 6 months in this group.
These early results suggest that outcomes with TCR
HaploSCTare better comparedwithour previous expe-
rience with TCD HaploSCT primarily because of im-
proved immune recovery posttransplantation. Longer
follow-up is necessary to confirm these findings [44].Alloanergized HaploSCTafter Ex Vivo
Costimulatory Blockade
T cell activation requires 2 signals from antigen
presenting cells (APCs): displayment of an immuno-
genic peptide on major histocompatibility complex
to T cell receptor and a costimulatory signal, most
commonly through CD80/86 on APCs to CD28
receptor on T cells. Blockade of the latter may result
in induction of anergy [55] and could allow successful
transplantation of histoincompatible allografts [56].
Guinan et al. [57] demonstrated the feasibility of Hap-
loSCT using a BM graft of which donor T cells were
anergized through incubation with the recipient’s
mononuclear cells and CTLA-4-Ig. CTLA-4 is
a counterreceptor for CD80/86 and has a much higher
affinity for it than CD28. Of 12 patients transplanted,
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sustained engraftment, and 3 had aGVHD. No deaths
because of GVHD occurred in this group. In a recent
update, Davies et al. [58] reported their experience in
24 patients with high-risk hematologic malignancies
or BM failure. Five patients developed severe aGVHD,
and 12 patients died within 200 days of transplantation
(5 because of infection). Eight patients were alive and
free of disease with a median follow-up of 7 years. Of
concern, none of the patients older than 18 years sur-
vived the first 200 days. A similar protocol revised to
minimize the early transplant-related mortality using
RIC and mega-doses CD341 hematopoietic stem cell
transplantation is currently in trials.
The Combination of G-CSF Primed Bone
Marrow and Mobilized PBSCs
G-CSF can induce T cell hyporesponsiveness and
a skewing toward a TH2 phenotype through an increa-
se in plasmacytoid dendritic cells and down-regulation
of CD28-CD80/86 signaling [59,60]. Based on these
findings, Chinese researchers developed a HaploSCT
protocol using myeloablative conditioning, inten-
sified immunologic suppression with antithymocyte
globulin, and a donor graft composed of G-CSF
primed bonemarrow and PBSCs [61]. In their most re-
cent update including 250 acute leukemic patients
[62], of whom 149 (60%) were transplanted while in
first complete remission with standard-risk genetics,
donors were treated with G-CSF 5 mg/kg/day subcu-
taneously and BM cells were harvested on fourth day of
G-CSF followed by collection of PBSCs on fifth
day. GVHD prophylaxis included cyclosporine,
MMF (both initiated on transplantation day 29),
antithymocyte globulin 2.5 mg/kg from days 25 to
22, and methotrexate on days 13, 16, and 111.
The early posttransplantation mortality rate ap-
proached 13%, and the cumulative incidence of grade
2 to 4 aGVHD was relatively high at 45.8%. The cu-
mulative incidence of cGVHD was 53.9% at 3 years,
which comes in sharp contrast with cGVHD rates ob-
tained with posttransplantation Cy. Overall, the 3-year
cumulative incidence of relapse was less than 20%, and
leukemia-free survival approached 70% among acute
myelogenous leukemia patients with standard risk dis-
ease (first or second complete remission without
Philadelphia chromosome) [62]. Even though a higher
disease-free survival was achieved—partly because of
inclusion of standard- and good-risk patients—the
concern remains that a higher incidence of GVHD is
usually associated with a higher treatment-related
mortality and higher cost of care for these patients.
In Vivo Depletion of T Cells
The anti-CD52 antibody, alemtuzumab (Cam-
path), has been used for in vivo depletion of hostand donor T cells to increase engraftment and decrease
GVHD rates in transplants from matched sibling or
unrelated donors [63-65]. Rizzieri et al. [66] treated
49 patients with hematologic malignancies using non-
myeloablative conditioning and alemtuzumab. The
preparative regimen included fludarabine and Cy on
days 25 to 22, and alemtuzumab 20 mg/day on days
24 to 0. Further GVHD prophylaxis included MMF
2 g/day for 45 days, with or without cyclosporine.
Three and 4 patients experienced primary and second-
ary graft failure, respectively. Twenty-four (49%) and
11 (22%) patients died of progressive disease and infec-
tions, respectively, whereas 2 (4%) patients died of
posttransplantation lymphoproliferative disease. One-
year OS was 31%. The relatively high relapse rate
observed was attributed partly because of the reduced
intensity of the conditioning. However, the disease re-
lapse rate may be further increased by the use of alem-
tuzumab, as recently reported in a Center for
International Blood and Marrow Transplant Research
registry analysis [67].NK Cells in HaploSCT
As previously detailed, NK cell alloreactivity may
be exploited to improve the efficacy and safety of
HaploSCT. It is thought that NK cells recognize their
targets through both inhibitory and activating recep-
tors. Various algorithms explaining NK cell alloreac-
tivity have been proposed [26,68-70]. According to
the widely used "missing self" model, an NK cell
recognizes a cell as foreign when the particular cell
lacks 1 or more HLA class I alleles specific to the
inhibitory receptors (killer immunoglobulin-like
receptors, KIRs) on the NK cell [26,71]. NK cells
attack primarily hematopoietic cells sparing the solid
organs, rendering them almost incapable of causing
GVHD [72]. Therefore, if the recipient cells lack the
HLA class I alleles specific to the donor KIRs, donor
NK cells may decrease the risk of GVHD and disease
relapse by killing the residual recipient APCs and leu-
kemia cells. Furthermore, following stem cell trans-
plantation, including TCD HaploSCT, NK cells are
the first lymphoid cells to recover by rapid differentia-
tion from engrafted stem cells [73].
Several studies evaluated the feasibility of NK cell
infusions after HaploSCT to utilize innate immunity
against different tumors [74-76]. Recently, Yoon
et al. [77] reported on a series of 14 patients with acute
leukemia or myelodysplastic syndromes in which
patients were infused with donor NK cells derived
from CD341 hematopoietic cells 6 to 7 weeks after
TCR HaploSCT. There were no acute side effects,
and 4 patients developed cGVHD. Four patients
were alive and disease-free 18 to 21 months posttrans-
plantation. Two patients who received NK cell infu-
sion during active leukemia did not have a response
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of NK cells post-HaploSCT.DONOR SELECTION
Most patients have more than 1 potential haploi-
dentical donor, and various factors have been impli-
cated in selection of the most suitable donor for
HaploSCT. We provide a summary of the most rele-
vant studies, which outlines the various factors consid-
ered in the decision to use 1 haploidentical donor
versus another.
KIR Mismatch
KIR mismatch between recipient and donor has
been associated with improved outcomes after
HaploSCT in several studies [78,79]. Ruggeri et al. [78]
reported improved graft rejection, GVHD, and dis-
ease relapse rates among patients with acute myeloge-
nous leukemia who received stem cells from donors
with KIR mismatches in the graft-versus-host direc-
tion compared with those without. More recently,
Symons et al. [79] reported similar results in a cohort
of 86 patients with various hematologic malignancies
who underwent TCR HaploSCT with nonmyeloabla-
tive conditioning and posttransplantation Cy with im-
proved NRM, OS, and event-free survival among
those transplanted with KIR mismatch donors com-
pared with those without [79]. Conversely, Huang
et al. [80] found KIR mismatch to be an independent
risk factor for aGVHD, relapse, and decreased OS in
a cohort of 116 patients after TCR Haplo SCT using
myeloablative conditioning. The conflicting results
may be partly because of differences in stem cell sour-
ces, treated diseases, type of conditioning, and varia-
tions in the definition of KIR mismatch. Although
NK cell alloreactivity is likely to play a role in the suc-
cess of HaploSCT, further studies are needed to better
define the role of KIRmismatch in donor selection and
exploit the NK alloractivity to improve outcomes post
transplantation.
Mismatched Maternal HLA antigens
Several clinical observations suggested that the
development of immunologic tolerance between
mother and fetus during pregnancy [81,82] could
impact the transplantation outcomes because of
a lifelong down-regulation of immune responses, if
the mismatched haplotype is of maternal origin, as
happens in transplants from a mother to her child, or
between siblings mismatched for noninherited
maternal HLA antigens (NIMA) compared with
noninherited paternal antigens (NIPA). Accordingly,
patients with maternal donors were found to have
longer OS after HaploSCT compared with those
with paternal donors in a Japanese registry study [83].Subsequently, van Rood et al. [84] demonstrated lower
aGVHD and cGVHD rates and lower treatment-
related mortality in T cell–replete haploidentical
transplant recipients NIMA compared with NIPA
mismatched. Separate studies later confirmed these
findings in patients transplanted from NIMA com-
pared with NIPA mismatch donors after both myeloa-
blative and nonmyeloablative regimens [85,86].
Number of HLA Mismatches between the
Donor and Recipient
Historically, increasing degrees of HLA mismatch
have been associated with shorter survival and higher
GVHD rates after Haplo SCT [10,87,88]. Recently,
the Johns Hopkins group reported that greater HLA
disparity was not associated with worse outcomes
after TCR HaploSCT with posttransplantation Cy
[89]. In this retrospective analysis of 185 patients
with various hematologic malignancies, having 3 or 4
total antigen or allele mismatches was not associated
with increased risk of grade II-IV aGVHD compared
with fewer mismatches. Moreover, in multivariate
analysis, the event-free survival of patients having 3
or 4 total antigen or allele mismatches appeared to be
better compared with those with fewer mismatches be-
cause of a lower relapse rate [89]. Although limited by
its retrospective nature, this study suggested that, by
using posttransplantation Cy, the higher treatment-
related mortality rates usually associated with more
mismatches can be eliminated, and improved out-
comes could be potentially achieved compared with
matched transplantation, as recently reported by the
Chinese group [90].
A multivariate analysis in a large cohort of patients
is needed to further elucidate the role of these factors
in donor selection for HaploSCT.FUTURE DIRECTIONS
Because of the universal and immediate availability
of haploidentical related donors for almost all patients,
including those from minority groups or with mixed
race, and the lower cost of HaploSCT compared
with unrelated donor transplantation, improvement
in this form of transplantation is warranted. Although
various methods have been used to overcome the sig-
nificant HLA barriers in HaploSCT, so far none has
excelled over another. However, we are encouraged
by the use of posttransplantation Cy because it pro-
vides a straightforward, effective way to control
GVHD posttransplantation without affecting engraft-
ment. This approach limits treatment-related mortal-
ity because of GVHD and possible infectious
complications, which, in our experience, occur more
frequently in TCDHaploSCT.However, relapse after
HaploSCT remains an issue because depletion of
378 Biol Blood Marrow Transplant 18:372-380, 2012U. D. Bayraktar et al.alloreactive T cells eliminates graft-versus-leukemia
effect, regardless of the method used. Future direc-
tions will likely include improvement in conditioning
regimens tailored to myeloid and lymphoid diseases,
the use of cellular therapy posttransplantation in an at-
tempt to decrease disease relapse, and possible replace-
ment of cyclophosphamide with other drugs to
selectively deplete alloreactive T cells posttransplanta-
tion in the future.ACKNOWLEDGMENTS
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